Rare Disease Therapeutics Introduces New Antivenom for Rattlesnake Bites

Rare Disease Therapeutics (RDT) announced the launch of ANAVIP [Crotalidae Immune F(ab') (Equine)] an equine-derived antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.

Rattlesnakes are found throughout the United States. The CDC estimates that the US incidence of venomous snake bites is 7,000-8,000 per year. Because people seek--and receive--rapid medical intervention, the number of deaths from snake bites is low (about 5 per year). However, coagulopathies (blood clotting disorders) can be major complications of a venomous rattlesnake bite, and one of the goals of treatment is to limit the potential incidence of latent (delayed) coagulopathy.  Because this new antivenom lasts longer in the body, it eliminates the need for scheduled maintenance doses.

Anavip was specifically engineered with a long half-life in order to minimize the likelihood of re-emergent venom effects (such as a drop in platelets, prolonged bleeding times, and other abnormal blood clotting tests) that commonly require additional doses of a shorter-acting antivenom.

"To make this advance possible, RDT partnered with a world-leader in antivenoms, Instituto Bioclon, S.A. de C.V. (Bioclon) / Laboratorios Silanes, S.A. de C.V.(Silanes)," said Milton Ellis, founder and CEO of RDT.  "We are pleased to add ANAVIP® to our expanding antivenom line, which includes the scorpion antivenom, Anascorp [Centruroides (Scorpion) Immune F(ab') (Equine) Injection], and a black widow spider antivenom which is now in development."

Jaime Silanes, CEO of Bioclon/Silanes said. "We are proud of our development collaboration with RDT, and we're equally proud to be manufacturing Anavip in our FDA-approved, state-of-the-art facility. We've worked closely with the FDA in order to bring this world-class facility on-stream to satisfy the high anticipated demand for Anavip in the United States."

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.